FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
|Articles|March 30, 2021
NICE Issues Positive Recommendation for Use of Kineret to Treat Still’s Disease
Author(s)BioPharm International Editors
NICE has issued a positive recommendation for Sobi's Kineret (anakinra) to be used as a first-line biologic therapeutic option for Still’s disease.
Advertisement
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Kineret (anakinra) to be used as a first-line biologic therapeutic option for Still’s disease.
In a March 31, 2021 press release, Kineret drug company, Sobi, revealed the recommendation, which also covers systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s Disease (AOSD). Still’s disease is a rare, serious inflammatory disorder that can present in adults as AOSD or children up to 16 years old as sJIA.
“We are pleased to receive this positive news for anakinra,” said Michael Oliver, vice-president and general manager, Sobi UK and Republic of Ireland, in the press release. “As a company we are committed to improving the lives of people with rare diseases and this recommendation will provide earlier access to anakinra in patients with Still’s disease and help to enhance their quality of life.”
“I welcome this positive recommendation for anakinra in relation to sJIA, as it offers an effective, therapeutic option for a disease which can be associated with significant morbidity among patients,” commented Professor A Ramanan, consultant pediatric rheumatologist, Bristol Royal Hospital for Children, in the press release.
“This final NICE guidance endorses that clinicians have the flexibility to use anakinra earlier in the patient pathway, as a first-line biologic therapy, which is something specialists in this area welcome and brings us closer to quicker disease control that would prevent progressive joint and systemic damage,” added Paul Brogan, professor of vasculitis and speciality lead, Paediatric Rheumatology, Great Ormond Street Hospital Institute for Child Health, in the press release.
Source:
Advertisement
Related to this article
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5